Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 河南羚锐制药股份有限公司是一家以药品、医疗器械生产经营为主业的国家高新技术企业和A股上市公司。公司拥有百余种骨科、心病科、脑病科、麻醉科产品,其中包括通络祛痛膏、壮骨麝香止痛膏、培元通脑胶囊、丹鹿通督片、胃疼宁片、参芪降糖胶囊、芬太尼透皮贴剂等国家中药保护品种和国家医保产品、基药产品。目前,控股、参股多家企业,拥有多个科研、生产基地,其中羚锐制药百亿贴膏剂生产基地领先国内,羚锐信阳健康产业园为国内先进的大型口服药生产基地。公司现有总资产逾40亿元,年创利税近9亿元。公司先后被评为“全国中药工业50强企业”、“全国中药系统先进集体”、“全国精神文明建设工作先进单位”、“国家重点高新技术企业”,公司党委被中组部命名表彰为“全国先进基层党组织”,2018年荣获“中国质量奖提名奖”,2019年,被认定为“国家绿色工厂”,2020年被河南省委、省政府表彰为“河南省抗击新冠肺炎疫情先进集体”,2021年被工信部认定为“国家技术创新示范企业”,2022年入选国家级“智能制造示范工厂”。 | ||||||||||||||||||||||||
Main Business | 药品的研发、生产与销售。 | ||||||||||||||||||||||||
Legal Representative | 熊伟 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 冯国鑫 | ||||||||||||||||||||||||
Solicitors | 北京市中伦律师事务所 | ||||||||||||||||||||||||
Auditors | 大华会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 0376-2973569 | ||||||||||||||||||||||||
Fax No | 0376-2987888 | ||||||||||||||||||||||||
Website | www.lingrui.com/ | ||||||||||||||||||||||||
600285@lingrui.com;fengguoxin@lingrui.com;maogaili@lingrui.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 18/10/2000 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 1.012 | ||||||||||||||||||||||||
DPS(RMB)* | ¥ 0.800 | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 4.921 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 12.749B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |